Background. The 13-item Patient Activation Measure (PAM-13) is an instrument that assesses people's knowledge, skills and confidence for self-management of their health and health care. Scores on the PAM-13 have been shown to predict adherence to health behaviours, health-related outcomes and health care costs. Objectives. To develop a European Spanish adaptation of the original PAM-13 and to examine its psychometric properties in a sample of chronic patients. Methods. The PAM-13 was forward-backward translated and then completed by chronic patients attending a primary health care centre. Data were analysed with a Rasch model. We assessed the functioning of the rating scale, its reliability, the item goodness-of-fit, differential item functioning (DIF), local dependence, unidimensionality and correlation analysis. Results. A total of 208 patients (80%) completed the questionnaire. Data showed a fit to the Rasch model. More than 50% of patients endorsed all the items. Item rank for the Spanish sample was similar to the original, with few differences. We found significant differences (P < 0.05) in PAM-13 measures according to adherence to prescribed medicines and positive correlations with selfefficacy and physical quality of life. Conclusions. The European Spanish PAM-13 is a reliable and valid instrument for assessing activation in patients with chronic disease in Spain. We suggest adding new items to the instrument so as to examine patients with higher activation levels in the future. Further studies are needed to evaluate the usefulness of this new Spanish PAM-13 in different settings and populations, as well as to examine the relationship between PAM-13 scores and other health-related outcomes.
Introduction
Health care systems are facing an era of increasing burden of chronic disease aggravated by ageing populations and the presence of multimorbidity (1) . Efforts to deal with these challenges involve not only improvements to health systems but also the requirement for patients to assume an active role in their self-care (2) . A key concept is patient activation, which refers to people's knowledge, skills and confidence for self-management of their health and health care (3) . Based on this definition, Hibbard et al. developed the Patient Activation Measure, a 13-item instrument (4) (PAM-13) that measures a person's selfconcept as a manager of his health and how competent he feels in taking on this role (5) .
The PAM-13 identifies four stages of activation (6): (i) 'Believes active role is important': patients do not yet believe they have an active or important role to play; (ii) 'Confidence and knowledge to take action': patients lack confidence and basic knowledge about their condition, treatment options and/or self-care; (iii) 'Taking action': patients have knowledge about their health condition, and some experience in adapting to behavioural changes, but may lack confidence or skills to support their behaviours; (iv) 'Staying the course under stress': patients may have adopted many behaviours needed to support their self-care, but may still find it difficult to maintain them over time or during times of stress. Research has shown that the PAM-13 can predict adherence to health behaviours, health-related outcomes and health care costs (5, 7, 8) . Patients with higher PAM-13 scores were more likely to eat healthily, to practise regular exercise, to engage in self-management routines, to have better physical parameters, as well as fewer hospital readmissions and visits to emergency units.
The PAM-13 has been examined in different population samples (9) (10) (11) (12) (13) , and it has been adapted to several languages (14) (15) (16) (17) (18) . In 2009, the PAM-13 was translated into Latin American Spanish; its psychometric properties were assumed to be similar to those of the original, and no equivalence study was carried out (19) . In Spain, southwestern Europe, the population of patients with chronic disease and multimorbidity is growing and the development of effective strategies for enhancing patient activation is a priority for the health care system (1) . The adaptation of the PAM-13 to European Spanish would provide an easy-to-use screening tool for assessing patients' relationships with self-management and would help providers to tailor care to the needs of chronic patients. Since the linguistic and cultural backgrounds of Latin American and European Spanish are not equivalent, a new Spanish translation and validation of the PAM-13 was needed. The aim of this study was to develop a European Spanish adaptation of the original PAM-13 and to examine its psychometric properties in a sample of patients with chronic disease.
Methods

Translation and adaptation process
After receiving permission and license materials from Insignia Health (6), the European Spanish translation and adaptation of the PAM-13 was performed in line with WHO recommendations (20) , which involves five stages: (i) forward translation, (ii) expert panel, (iii) back-translation, (iv) a pre-test and cognitive interviewing and (v) consensus on the final version.
Three Spanish native speakers with knowledge of English and a background in health care research conducted an independent translation and discussed discrepancies among their translations until reaching consensus. This was then back-translated by an independent native English speaker with experience in questionnaire translation.
Refinement of item wording was carried out using a convenience sample of patients with chronic disease (n = 10). After completing the questionnaire, a debriefing interview with each participant was used to introduce any changes required to improve the understandability of items. The final European Spanish PAM-13 version comprised 13 items which respondents rated on a four-point scale, from strongly disagree (1) to strongly agree (4). We decided not to include the category 'not applicable' so as to avoid misinterpretations. Supplementary Table S1 shows the differences in wording between the Latin American and the European Spanish versions.
Data collection
The translated PAM-13 was completed by a convenience sample of patients attending a primary health care centre (PHC) in Terrassa (city near Barcelona), which provided care to 215 214 patients during 2015 (21) . Inclusion criteria were age >18 years and a recorded diagnosis of at least one of the following chronic diseases or risk factors as defined by WHO (22) : diabetes mellitus 2, high blood pressure, dyslipidemia, chronic obstructive pulmonary disease (COPD), heart failure, rheumatoid arthritis or chronic kidney disease. Exclusion criteria were: a recorded diagnosis of severe mental disorder, cognitive impairment assessed with the Short Portable Mental Status Questionnaire (SPMSQ) (23) , inability to read, or inability to understand or speak Spanish.
Data collection ran from February to May 2015. Every week, one of the researchers reviewed the list of patients who had an appointment with their nurse or physician at the PHC during the coming week and identified those who met the inclusion criteria. During their appointment, target participants were invited to enrol in the study by their nurse or physician, who explained that a new test for assessing patients with chronic disease was currently being evaluated. Those who expressed a willingness to take part were contacted by the researchers to explain the aims of the study. If they agreed to participate, they were invited to complete the anonymous questionnaire in the consultation or at home. The Ethics Committee of the study centre reviewed and authorised the study protocol. Directives of the Helsinki Statement, Belmont Report principles and local laws were respected. Informed consent to participate in the study was obtained.
Variables and measures
We also recorded sociodemographic data, diagnoses of chronic conditions and multimorbidity status (defined as a person with two or more chronic diseases) (24) .
Satisfaction with health care was assessed with the item 'How satisfied are you with the healthcare system?', rated on a four-point scale from very unsatisfied (1) to very satisfied (4) . Anxiety and depression symptoms were assessed using the Goldberg Anxiety and Depression Scale (GADS) (25) . Scores ≥4 on the anxiety items and ≥2 on the depression items were interpreted as indicating that the patient had a 50% chance of suffering from a clinically important disturbance. Adherence to prescribed medication was measured using the Morisky Medication Adherence Scale (MMAS) (26) ; no adherence was considered when one or more items were answered with 'yes'.
Analysis and statistical methods
The psychometric properties of the European Spanish PAM-13 were studied using the same analytic procedure as that applied when developing the original PAM-13 (4). Specifically, a Rasch model was used to examine how each item from the PAM-13 contributed to the patient activation construct. Rasch analysis arranges both items and individuals hierarchically using the same metric; in this case, items are ordered according to their difficulty (i.e. how much activation is required to endorse the item, from less to more) and individuals according to their stage of activation (from first, 'Believes active role is important', to fourth, 'Staying the Course under Stress'). Rasch analysis requires examination of data quality and confirmation that the data fit the Rasch model. Only PAM-13 questionnaires that were returned with seven or more items answered were included in the analysis. Rasch Winsteps® v3.91 software was used to study fit to the Rasch model, with SPSS v.22 being used for the statistical analysis.
Rasch analysis
We applied the Rasch rating scale model (RSM) for polytomous responses after testing it against the partial credit model (PCM) using the likelihood ratio statistic. The RSM was appropriate as all items shared the same rating scale.
The functioning of the rating scale was analysed in accordance with the following criteria (27) : (i) each category of the RSM must have at least 10 observations, (ii) average measures (expressed in logits, the mathematical unit of Rasch Measurement) should be ordered and (iii) Rasch-Andrich thresholds-the point where there is a 50% probability of a response falling in one or another adjacent category-should be listed in ascending order according to the categories. Once the structure functioning was verified, reliability was evaluated with the Item Separation Index which is comparable to Cronbach's alpha: values ≥ 0.7 show the scale differentiated between individuals and items along the latent trait.
The item's goodness-of-fit to the model was studied using infit and outfit mean-square statistics: values ranging from 0.7 to 1.4 indicate acceptable measurement estimations (28) . Differential item functioning (DIF) hypothesises that items reflect the same theoretical construct but may differ quantitatively in terms of how they function in differing populations. Items with DIF may affect the estimated robustness of the test. This aspect was examined by considering gender, age (<65 and ≥65 years), educational level (secondary education or below) and multimorbidity status (Yes, No). DIF was analysed by computing differences between the item measures for each group anchored to the whole group; DIF was considered to be present if the Z test with Bonferroni correction was significant.
Unidimensionality of the items is an assumption of the Rasch model, which means that the scale measures the single construct, in this case patient activation. We inspected the unidimensionality of the Patient Activation scale to confirm that all of the non-random variability of the data was accounted for by a single dimension. We used a principal component analysis of residuals (PCAR). An eigenvalue <2 of the first component indicated that the construct of the items was unidimensional (29) . Local independence-the correlation between items that might inflate the Rasch estimation-was examined with the correlation matrix of the standardised residuals of the PCAR. We interpreted residual correlations <0.3 as verifying the independence of items.
Once data quality in the Rasch model had been verified, we compared the ranking of the items to other adaptations of the PAM-13 that used Rasch analysis. We expected to find a similar item rank between the original PAM-13 (4) and the adapted to European Spanish. We also examined the correlation between selfefficacy [using the General Self-Efficacy Scale (30) , where higher scores (11-40) indicate higher status], quality of life (using the SF-12 Questionnaire (31) which reports a Physical and a Mental Component Summary), visits to the emergency room and number of hospitalisations using the Pearson correlation coefficient in order to explore the concurrent validity of the scale.
Overall differences in activation between groups (gender, age, educational level, multimorbidity, anxiety or depression, satisfaction with health care system and medication adherence) were tested using Student's t-tests for the overall patient mean location of each group. A significant mean group variation (P < 0.05) indicates different activation between groups.
Results
Administration of the Patient Activation Measure 13
Two hundred and sixty patients were initially contacted of whom 36 (13.8%) declined to participate. Two hundred and eight completed the questionnaire (response rate 80%); the remaining 16 patients (6.2%) either did not return the survey or left it incomplete. Figure 1 is a flow chart of the recruitment process. Mean age was 65 years (SD = 9.45), ranging from 37 to 87. Most of the participants were male, married, retired and with only primary-level education. The most frequent chronic disease diagnoses were high blood pressure (69.2%), type 2 diabetes (66.3%), dyslipidemia (49%) and COPD (25.5%). More than one chronic disease was recorded in 76.4% (N = 159) of participants. Table 1 displays the sociodemographic and other patient data.
Rasch analysis
As the likelihood ratio statistic was not significant (χ 2 = 33.94, df = 78, P = 1.00), the Rasch rating scale model was preferred over the Rasch PCM. All criteria for rating scale functioning were satisfied. The European Spanish PAM scale had an item separation index for the parameters of 6.64, with optimal reliability of 0.98. Infit and outfit statistics showed adequate goodness-of-fit of the items. Table 2 shows values for item difficulty (how much activation is required to endorse the item) in rank order, from least to greatest (from top to bottom of the column).
Mean activation was 2.00 logits (SD = 1.54). All patients showed maximum endorsement of activation on item 2 (' Taking an Data were collected between February and May 2015 in a PHC located in Terrassa, a city near Barcelona. During a standard appointment, target participants were invited to participate in the study by their nurse or physician who explained that a new test for assessing patients with chronic diseases was being assessed.
am confident I can figure out solutions when new situations or problems arise with my health condition'), with 62.98% (n = 131) and 57.21% (n = 108) endorsement, respectively.
No relevant evidence of DIF was found, and we therefore considered that activation values across groups were robust. In the unidimensionality test, the eigenvalue of the first component of the PCAR was 1.8, confirming the hypothesis that the 13 items of the PAM scale could be aligned along the same continuum of patient activation; all residual correlations between pairs of items were <±0.3, indicating no relevant local dependence. Table 3 shows the item rank for the current PAM-13 validation (right column) compared with other PAM-13 adaptations and the original (left column). The shading in the table reflects the four stages of activation described by the authors of the PAM-13 (4). The item rank for the Spanish sample was similar to that obtained in the USA (10) and Canada (9), except for item 13, which dropped from the fourth stage of activation (Staying the course under stress) to the third (Taking action), and item 9, which moved up from the third to the fourth stage. Other PAM-13 adaptations showed more variation in item rank in comparison with the original PAM-13. The item goodness-of-fit to the model was studied using infit and outfit mean-square statistics: values ranging from 0.7 to 1.4 indicate acceptable measurement estimations (28) . Table 3 . Differences in item rank between the original PAM-13, the current Spanish PAM-13 and other international adaptations of the PAM-13
Item rank for the original PAM-13 and adaptations in other languages
Original
Denmark (14) Germany (15) USA (10) Korea (18) Canada (9) Spain 1  1  2  1  1  1  2  2  3  6  2  2  2  1  3  2  8  4  5  4  7  4  7  4  6  6  7  4  5  8  7  7  9  6  3  6  6  1  3  10  5  6  7  4  10  5  3  8  5  8  11  5  8  13  9  8  9  10  3  9  11  3  10  10  9  9  10  12  11  13  11  5  11  11  7  10  11  12  12  13  13  8  12  9  13  13  12  12  4  13  12 The shading indicates the stage of activation (i.e. how much activation is required to endorse the item), as described by Hibbard et al. (3) . From lighter to darker: (i) Believes active role is important; (ii) Confidence and knowledge to take action; (iii) Taking action; (iv) Staying the course under stress.
Relationship with other variables
We found a significant difference in patients' activation according to medication adherence, and a trend to significance in relation to educational level. Patients with more education and greater medication adherence scored higher on the PAM-13 (Table 4) .
Pearson correlation coefficients between Rasch measures of the European Spanish PAM-13 and other measures were significant only with Self-efficacy (r = 0.21, P < 0.01) and the Physical Component Summary (r = 0.14, P < 0.05) of the SF-12 questionnaire (Supplementary Table S2 ).
Discussion
The translation and adaptation process resulted in an equivalent instrument, and the analysis of psychometric properties showed that this European Spanish PAM-13 is a valid and reliable measure for use in chronic disease patients in Spain.
Our patients showed high levels of activation: they all endorsed the first three items, and more than 50% endorsed all the others. Similar results were found in Germany (16) and the USA (10) where, interestingly, study samples were similar to ours, since they were formed by primary care patients. We agree with those authors who suggest that adding two or three new items would enable even higher levels of activation to be identified (16); a fifth stage of activation would allow better targeting, and would increase the effectiveness of the PAM as a clinical assessment tool. This issue warrants further research in patients with higher levels of activation.
The item rank for the European Spanish adaptation of the PAM-13 was similar to that of the original (4), although the clinical samples were slightly different; while we studied chronic patients seen at a primary care centre, the original PAM-13 scale was studied in a randomised national sample. Only two items (9 and 13) did not reproduce the corresponding stage of activation in the original. Although this mistargeting could be due to clinical and cultural differences between participants, there are other plausible explanations. Item 9 (I know the different medical treatment options available for my health condition) was found to be one of the most difficult, making it part of the fourth stage rather than the third as expected. This increase in item level of activation may relate to the issue of communication and shared decision-making between clinicians and patients. Recent studies in Spain have shown that both patients and health care professionals perceive problems in having an active voice when working together in the decision-making process (32, 33) . The greater level of activation observed in item 9 would be consistent with this and suggests that this communication issue affects patients' activation. The mistargeting of item 13 (I am confident that I can maintain lifestyles changes like diet and exercise, even during times of stress) was in the opposite direction, as was easier compared with the original PAM-13. We hypothesised that this mistargeting was due to a stronger sense of self-efficacy in our patients, a component of the patient activation construct that refers to a person's belief in his ability to successfully accomplish something (12, 16) . As expected, we found a positive correlation between self-efficacy and the PAM-13; however it was weaker than in studies with different clinical samples (10, 12, 16, 17) . Similarly, we found positive correlations between the PAM-13 and the physical component of the SF-12. Although this correlation was not high, it was similar to previous studies (9, 13) .
Differences between the current Spanish version and the original PAM-13 compare favourably with the greater variations in item rank found in other validations of the scale. The fact that we compared the item rank order across different adaptations of the PAM-13 constitutes, in our view, a step forward in research on the validity and usefulness of the scale internationally.
The differences in adherence to prescribed medicines are consistent with previous findings showing that higher PAM-13 scores are associated with engagement in self-care behaviours, such as medication adherence (5, 7, 8) . However, this result cannot be generalised, since a recent systematic review (34) was unable to conclude decisively that there was an association between PAM scores and medication adherence in chronically ill populations, due to inconsistent results in the literature. In line with other studies (9, 11, 35) , we also identified a trend towards a significant association between PAM-13 scores and educational level. It should be noted, however, that whereas the original PAM-13 study found that higher scores were associated with female gender and younger age (4), this association was not observed here.
Strengths and limitations
The European Spanish adaptation of the PAM-13 has similar psychometric properties to the original scale, thus warranting its future application in the clinical and research context in Spain. However, as our patients were recruited from the PHC where they 
Conclusions
This Spanish adaptation of the PAM-13 is an equivalent instrument, valid and reliable for assessing activation in patients with chronic disease in Spain. The order of items was similar to that of the original version, with only two items being assigned to a different stage of activation. The fact that our sample overall was highly activated suggests that new items targeting higher levels of activation may need to be developed. Future studies should assess the usefulness of this new Spanish PAM-13 in different settings and populations, and also examine the relationship between PAM-13 scores and self-care behaviours and other health-related outcomes.
